¿Cuál es su costo-efectividad? | 26 MAR 17

Pruebas de tamizaje del cáncer colorrectal en la Argentina

La evidencia internacional confirma que el tamizaje de cáncer colorrectal (CCR) es costo-efectivo, sin embargo, en Argentina este dato es desconocido

Autor/a: Natalia Espinola, Daniel Maceira, Alfredo Palacios Acta Gastroenterol Latinoam 2016;46:8-17

INDICE: 1. Página 1 | 2. Página 1

Página 1

IARC-Globocan, 2012. http://globocan.iarc.fr/Pages/fact_sheets_ population.aspx
Gualdrini UA, Iummato LE. “Cáncer colorrectal en la Argentina: Organización, cobertura y calidad de las acciones de prevención y control. Informe final de diciembre de 2011: Diagnóstico de situación de la Argentina. Propuesta del Programa de prevención y detección temprana, y acciones para su implementación”. Instituto Nacional de Cáncer.
Sharp L, Tilson L, Whyte S, O’ Ceilleachair A, Walsh C, Usher C, Comber H. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. British Journal of Cancer 2012; 106: 805-816.
Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. Canadian Medical Association Journal 2010; 182: 1307-1313.
Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening–an overview. Best Practice & Research Clinical Gastroenterology 2010; 24: 439-44
DEIS. Agrupamiento de causas de mortalidad por división política territorial de residencia, edad y sexo, Argentina, año 2012. Boletín Número 144, Mayo 2014.
Sack J, Rothman J. Colorectal Cancer: Natural History and Management. Hospital Physician October 2000; 64-73.
Bujanda L, Cosme A, Gil I, Arenas-Mirave JI. Malignant colorectal polyps. World J Gastroenterol 2010; 16: 3103-3111.
Fernández Marcos A, Pastor A, Pérez Segura P, Castells A, López- Bastida J, Camacho S, González T, Morillas J. Cribado del cáncer de colon en España. ¿Es costo-eficaz? Alianza para la Prevención del Cáncer de Colon en España. Madrid 2010.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, IARC Scientific Publications IX (16). Lyon: IARC; 2007.
Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009; 125: 171-180.
Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN, 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base Nº 10, Lyon, France: International Agency for Research on Cancer, 2010.
Encuesta Nacional de Factores de Riesgo (ENFR), 2009. Ministerio de Salud de la Nación Argentina.
Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screeninga systematic review for the US Preventive Services Task Force. Annals of Internal Medicine 2002; 137: 96-104.
van Rossum LG, van Rijn AF, Verbeek AL, van Oijen MG, Laheij RJ, Fockens P, Jansen JB, Adang EM, Dekker E. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: A cost‐effectiveness analysis. International Journal of Cancer 2011; 128: 1908-1917.
Rabeneck L1, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, Messersmith H, Lewis N. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Canadian Journal of Gastroenterology 2012; 26: 131.
Lejeune C, Le Gleut K, Cottet V, Galimard C, Durand G, Dancourt V, Faivre J. The cost-effectiveness of immunochemical tests for colorectal cancer screening. Digestive and Liver Disease 2014; 46: 76-81.
Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Diseases of the Colon & Rectum 2011; 54: 876-886.
Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, Kuipers EJ, van Leerdam ME, van Ballegooijen M. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013; 62: 727-734.
Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc 1991; 37: 125-127.
Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-60.